Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
Although the decrease is not sufficient, the first therapeutic vaccine, designed from the dendritic cells of the actual patient by the Hospital Clinic of Barcelona-IDIBAPS has achieved a significant response in the majority of patients
2011-02-02
(Press-News.org) The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments. The final aim of the therapeutic vaccines will be to avoid a life long treatment with antiretroviral drugs. The research team 'Infectious Diseases and AIDS' led by Dr. Josep Maria Gastell from IDIBAPS – Hospital Clínic has developed using the brand HIVACAT, a model of the therapuetic vaccine based on the patient's own dendritic cells. This reduction in the viral load is still considered to be insuficient but it is the first therapeutic vaccine which has achieved a postive response in the majority of patients.
The Journal of Infectious Diseases has published the results of this study with Dr. Felipe García from the Infectious Diseases Unit of IDIBAPS – Hospital Clinic, as first author and Dr. Teresa Gallart from the Immunology Laboratoy of the same centre as last author. The work counted on an international collaboration with teams from France, the Hôpital Pitié-Salpêtriére and the Université Pierre et Marie Curie in Paris/INSERM, and the USA, the National Institute of Cancer in Maryland.
A total of 24 patients participated in this double blind clinical trial, half of whom formed the control Group and who did not receive the vaccine. None of these patients received antiretroviral treatment and to enter into the study had to maintain a good T lymphatic blood load (>450 per mm3). The vaccine was personalized and was made from the dendritic cells of each patient sensitized in the laboratory against an inactive form of their own virus. We are looking at a cell therapy that in the ambit of IDIBAPS received support from the Cell Therapy programme of the University of Barcelona. The vaccine was administered in 3 dosis with an interval of 2 weeks between each one.
At the end of 24 weeks, it showed that the majority of patients had experienced a significant decrease in the viral load. This decrease was very significant is some of them but in no case did the virus become undetectable. However this is a very important improvement with respect to previous initiatives where with a similar vaccine there was a modest response in 30% of the treated patients. No therapeutic vaccine has achieved up to now the same level of response as in this study. A new clinical trial is underway testing the administration of the vaccine in conjunction with antiretroviral drugs to allow an improvement in the results.
The principal objective of therapeutic vaccines is to minimize the need for antiretroviral drug treatment. These treatments have improved enormously over the past few years and have become easy drugs to administer with few side effects. Although the daily administering is not ideal, there is no experience over the long term and it is not known if the treatment could bring about resistance. It aims to deal with the treatment of chronic patients for their whole life which currently is an important economic burden for the health system. The annual budget for antiretrovirals in Hospital Clinic is around 30 Million Euros. Furthermore the therapeutic vaccine is easy to produce and small administrations could be implemented in developing countries, too. To undertake this ambitious objective there has to be a continuing scientific and economic efforts in initiatives such as HIVACAT.
INFORMATION:
About HIVACAT
The HIVACAT AIDS vaccine research and development project is a joint private and public sector-funded consortium without precedent in Spain, placing our country to the fore of HIV and AIDS research internationally. Consisting of the two of most important and established AIDS research centres in the country, the IrsiCaixa Institute for AIDS Research and the AIDS and Infectious Diseases Service at Barcelona's Hospital Clìnic, HIVACAT carries out research into the development of a new vaccine against HIV in coordination with ESTEVE, and with the support of the "La Caixa" Bank Foundation ("Fundació la Caixa"), the Department of Health and the Department of Innovation, Universities and Companies of the Generalitat de Catalunya, Catalonia's autonomous government. This consortium is the first major attempt at establishing collaboration in this field between local government, researchers and companies.
In Spain, the project is co-directed by Dr Bonaventura Clotet from IrsiCaixa and Dr Josep Maria Gatell from Barcelona's Hospital Clìnic. Both research centres are conducting research alongside 5,000 patients who benefit from both the rapid incorporation of new treatments developed directly in the two centres, and innovations achieved internationally. HIVACAT consists of a team of more than 60 scientists trained in prestigious international research centres such as the University of Harvard in the United States, l'Insitut Pasteur in Paris, and London's Royal Free Hospital.
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-02-02
BLACKVILLE, S.C. — The furry-looking insects start their development smaller than the head of a pin, but the caterpillars soon develop an appetite for cotton as big as the crop.
To demonstrate the insects' destructive power, Clemson University entomologist Jeremy Greene planted two cotton varieties — one genetically modified to provide protection from caterpillars, one not — in a demonstration field at the Edisto Research and Education Center.
The non-protected cotton was planted in a pattern that spelled the word "Tigers." Aerial photographs taken near harvest show ...
2011-02-02
Reston, Va. (February 1, 2011) — Positron emission tomography (PET) can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine. Currently being tested in clinical trials, vandetanib inhibits the function of the RET (rearranged-during-transfection protein) proto-oncogene and other protein kinases involved in the development and progression of cancer.
"For the most ...
2011-02-02
(Phoenix, Arizona February 1, 2011) -- Research by a Barrow Neurological Institute scientist on the thermoregulatory effects of a receptor more commonly studied for its role in pain is the cover story in the Feb. 2 issue of the Journal of Neuroscience. The research was conducted by an international team led by Andrej Romanovsky, MD, PhD, Director of the Systemic Inflammation Laboratory (FeverLab), at Barrow, which is a part of St. Joseph's Hospital and Medical Center.
The featured research discovers a new role of TRPV1 (transient receptor potential vanilloid-1) receptors ...
2011-02-02
WASHINGTON — Talking with your hands can trigger mental images that help solve complex problems relating to spatial visualization, an important skill for both students and professionals, according to new research published by the American Psychological Association.
Spatial visualization is the ability to mentally rotate or move an object to a different position or view. An air traffic controller uses spatial visualization to mentally track planes in the air based only on a two-dimensional radar screen. An interior decorator needs spatial visualization to picture how ...
2011-02-02
In order understand the evolution of complex societies, researchers are sequencing the genomes of social insects. The most recent data, published this week in the Early Edition of Proceedings of the National Academy of Sciences, come from several species of ants, including the red harvester ant, Pogonomyrmex barbatus.
A team, lead by Arizona State University organismal and systems biology professor Juergen Gadau, sequenced one of the genomes and set out to decipher which genes might be responsible for defining which ants work and which ants reproduce in a red harvester ...
2011-02-02
Invasive plant species are a serious environmental, economic and social problem worldwide. Their abundance can lead to lost native biodiversity and ecosystem functions, such as nutrient cycling.
Despite substantial research, however, little is known about why some species dominate new habitats over native plants that technically should have the advantage.
A common but rarely tested assumption, say biologists, is that these plants behave in a special way, making them more abundant when introduced into communities versus native plants that are already there.
If true, ...
2011-02-02
It has already been called one of the largest winter storms since the 1950s and it is affecting 30 U.S. states today with snow, sleet, freezing rain and rain. NASA satellites have gathering data on the storm that stretches from Texas and the Rockies to the New England states.
NASA's Aqua and Terra satellites have been providing visible, infrared and microwave looks at the storm system's clouds, precipitation, temperatures and extent.
Visible and infrared images and animations of the storm's clouds and movement are created every 15 minutes by the NASA GOES Project at ...
2011-02-02
Human amniotic epithelial cells, stem cells derived from human placenta left over from live births and generally discarded, proliferated and differentiated when they interacted with one kind of melatonin receptor, MT1. This potentially therapeutic response occurred when the stem cells were transplanted into laboratory test tube and animal models of stroke. The same cells did not perform similarly when interacting with melatonin receptor MT2.
Researchers from the University of South Florida's Department of Neurosurgery and Brain Repair, and co-researchers in Brescia, ...
2011-02-02
Hepatitis C is a leading cause of illness and death for individuals infected with both HIV and hepatitis C. Recent reports from around the world demonstrate that hepatitis C is emerging as a sexually transmitted infection among HIV-infected men who do not inject drugs. However, many HIV-infected men do not receive continued screening for hepatitis C throughout their HIV care. Hepatitis C symptoms often do not manifest themselves until the later stages of the illness, so people are not as likely to know that they have become infected and hence need further testing and ...
2011-02-02
Several NASA satellites have been monitoring the growth of powerful and massive Cyclone Yasi and providing data on clouds, rainfall and intensity to forecasters as it nears Queensland, Australia. NASA data shows where the heaviest rainfall is occurring, frigid temperatures at the top of its thunderstorms and the size of Yasi's eye.
Tropical cyclone Yasi became much more powerful and was upgraded to a dangerous category fpur tropical cyclone on the Saffir Simpson scale on February 1, 2011.
A Cyclone Warning is now in effect for Queensland, Australia for coastal areas ...
LAST 30 PRESS RELEASES:
[Press-News.org] Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
Although the decrease is not sufficient, the first therapeutic vaccine, designed from the dendritic cells of the actual patient by the Hospital Clinic of Barcelona-IDIBAPS has achieved a significant response in the majority of patients
